WO1998052617A2 - Contrast media for imaging of lung draining lymph nodes, administered through the lungs - Google Patents
Contrast media for imaging of lung draining lymph nodes, administered through the lungs Download PDFInfo
- Publication number
- WO1998052617A2 WO1998052617A2 PCT/GB1998/001489 GB9801489W WO9852617A2 WO 1998052617 A2 WO1998052617 A2 WO 1998052617A2 GB 9801489 W GB9801489 W GB 9801489W WO 9852617 A2 WO9852617 A2 WO 9852617A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- contrast agent
- lung
- animal
- lungs
- particulate
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0476—Particles, beads, capsules, spheres
- A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1815—Suspensions, emulsions, colloids, dispersions compo-inhalant, e.g. breath tests
Definitions
- This invention relates to contrast agents for imaging of the lung draining lymph nodes, and to methods of in vivo imaging of lung draining lymph nodes .
- Lung cancer is responsible for a major proportion of cancer diagnoses, representing some 200000 new cases per year in the USA alone. Suspected and confirmed cases are staged by CT (X-ray) scanning of lymph nodes with the physician looking at the size of the nodes . Big nodes are assumed to contain metastatic disease while smaller nodes are assumed to be disease free. This however is by no means always the case. Large lymph nodes may simply be inflamed and not cancerous while small nodes can be infiltrated with metastatic cells. Accordingly, the patients' treatment and prognosis is often decided upon relatively inaccurate information. Besides CT-scanning, the only other conventional diagnostic check is mediastinoscopy, a surgical procedure which involves removal of the mediastinal lymph nodes and histopathologic assessment of disease state. This surgical procedure is usually only done efficiently at large tertiary cancer centres .
- the invention provides a method of in vivo imaging of lung draining lymph nodes, said method comprising administering into the lung of an air breathing animal (e.g. a human or other mammal, or a reptile or bird), e.g. by direct instillation into the airways of the deep lung or at or near sites of particular interest, a diagnostically effective amount of a physiologically tolerable, substantially water-insoluble, particulate contrast agent, and after a period of time sufficient for uptake of particles of said contrast agent by lung draining lymph nodes generating an image of at least part of the lungs of said animal, e.g. by using an X-ray, MR, nuclear or ultrasound diagnostic imaging modality.
- an air breathing animal e.g. a human or other mammal, or a reptile or bird
- a diagnostically effective amount of a physiologically tolerable, substantially water-insoluble, particulate contrast agent e.g. by direct instillation into the airways of the deep lung or at or near sites of particular
- the invention provides the use of a physiologically tolerable, substantially water-insoluble, particulate contrast agent for the manufacture of a diagnostic contrast agent composition for use in a method of diagnosis involving administration of said composition into the lungs of an air-breathing animal and, after a period of time sufficient for uptake of particles of said contrast agent by lung draining lymph nodes, generating an image of at least part of the lungs of said animal.
- the invention provides a contrast agent composition for use in a method of diagnosis involving administration of said composition into the lungs of an air-breathing animal and after a period of time sufficient for uptake of particles of said contrast agent by lung draining lymph nodes generating an image of at least part of the lungs of said animal, said composition comprising a physiologically tolerable, substantially water- insoluble, particulate contrast agent together with at least one physiologically tolerable carrier or excipient, e.g. a gas or gas-precursor or a liquid.
- a physiologically tolerable carrier or excipient e.g. a gas or gas-precursor or a liquid.
- the invention provides a contrast agent composition package comprising an aerosol or powder dispenser containing a physiologically tolerable substantially water-insoluble, particulate contrast agent optionally together with at least one physiologically tolerable carrier or excipient, e.g. a gas or gas-precursor or a liquid such as water.
- a physiologically tolerable carrier or excipient e.g. a gas or gas-precursor or a liquid such as water.
- the particulate contrast agent used according to the invention may be particles of any substantially water-insoluble, physiologically tolerable material capable of enhancing contrast in the diagnostic imaging modality of choice.
- the particles may be liquid droplets or flexible vesicles but more preferably will be solid particles.
- substantially water-insoluble is meant that the particles do not dissolve in the lung fluids to any significant extent, e.g. particles of up to 1% which by weight dissolves in water at 37°C in 10 days.
- the particle size should desirably be as uniform as possible, e.g. 90% or more by number should desirably be within 10% of the numerical mean particle size, ie . substantially monodisperse .
- the mean particle size will desirably be in the range 1 to lOOOOnm, preferably 5nm to l ⁇ m, especially preferably 8 to 400nm.
- Such particles can be prepared by precipitation or emulsification techniques or by milling.
- the particles will desirably be of an iodine or heavy metal (i.e. atomic number 37 or greater) containing material, e.g. a bismuth, tungsten or barium compound such as barium sulphate or a solid or liquid iodinated compound (e.g.
- the contrast agent is preferably an inorganic ferromagnetic, ferrimagnetic, superparamagnetic or paramagnetic material optionally provided with a coating or matrix material, e.g. a polymeric coating such as a silane or polystyrene.
- Nanometer sized iron oxide particles i.e. SPIO's or USPIO's, namely particles of the type present in Nycomed' s ABDOSCAN product or Advanced Magnetic 's Biomag M4200 product or as described in PCT/GB97/00067 may thus be used.
- particles of gadolinium oxalate or another relatively insoluble paramagnetic compound may be used.
- paramagnetic metal compound loaded molecular sieve particles e.g. particles of the type used in Gadolite
- insoluble particles of gadolinium loaded polychelants e.g. loaded dendrimeric macrocyclic chelant carrying compounds (see for example WO93/06868) , may be used.
- any echogenic material may be used as a contrast agent and these may, for example, be particles of greater or lesser density than the body fluid in the lymph nodes, e.g. inorganic particulates (e.g. barium sulphate) or gas filled synthetic polymer capsules.
- Suitable gases are described in PCT/GB97/00459 and WO-96/40285 (Unger) . Preferred as gases are air, perfluorobutane and perfluoropentane .
- the capsule material may be any biotolerable polymer or cross-linked membrane forming material, see for example W093/17718 and EP-A-458745.
- appropriate contrast enhancing substances may be used.
- the contrast agent is an X-ray contrast agent and in particular an insoluble, solid (at 37°C) iodinated compound.
- the contrast agent will generally be administered as a dry powder dust or as a liquid aerosol and conventional liquid suspension media, e.g. water for injections, saline, phosphate buffered saline, and mixed aqueous/non-aqueous solvent systems (eg. aqueous alkanolic solutions) may be used.
- the compositions administered may contain further components, such as stabilizers (e.g. polyalkylene oxides, such as pluronics) , surfactants, dispersants, pH and osmolality adjusting agents, antioxidants and the like.
- the composition administered may be entirely composed of contrast agent or may for example contain as little as 0.001% w/w contrast agent.
- the actual content clearly will depend on the imaging modality used. However, generally the composition will contain 1 to 99% w/w contrast agent, more preferably 10-70%, for CT and X-ray imaging procedures.
- the contrast agent may be filled into inhaler devices of the type conventionally used for administration of dry powders or aerosols into the lungs.
- these devices will be metered inhalers so that a predetermined amount of contrast agent is delivered per activation.
- the required contrast agent dosage may then be delivered by multiple activations of the device.
- Devices of the kind disclosed in W096/19253, WO96/04948, WO92/10229 and WO92/09323 are preferred.
- the contrast agent may be instilled directly into the lungs via a tube inserted through the mouth or nose . Direct instillation via bronchoscopy into the deep lung or to the region of a lesion of interest is preferred.
- the contrast agent will preferably be delivered as a dry powder or an aerosol spray, or as a liquid suspension.
- the total dosage of contrast agent required will clearly depend on the subject under study and the imaging modality used. Generally however contrast agent dosages will be 0.1 to 500 mg/kg bodyweight, preferably 0.1 to 200 mg/kg, or 10 5 to 10 20 particles/kg bodyweight, preferably 10 7 to 10 15 particles/kg.
- the dosage will preferably be in the range 20 to 400 mg/kg, more preferably 60 to 200 mg/kg; for MR imaging with paramagnetic particulates 0.1 to 10 mmol paramagnetic metal/kg; for MR imaging with superparamagnetic particles 1 to 100 mg/kg; for ultrasound imaging with inorganic particulates 0.1 to 100 mg/kg, more preferbly 1 to 20 mg/kg; and for ultrasound imaging with gas or gas precursor containing particles (e.g. vesicles, micelles, liposomes, microballoons, etc.) 0.1 to 100 mg/kg, more preferably 1 to 20 mg/kg.
- gas or gas precursor containing particles e.g. vesicles, micelles, liposomes, microballoons, etc.
- Image generation will suitably be effected after contrast agent transport to the lung draining lymph nodes has occurred, e.g. 120 mins to 60 days, preferably 2 to 40 days, especially preferably 6 to 20 days after contrast agent administration.
- image generation may be effected after even longer delays, e.g. up to 60 days. It is preferred that the delay before image generation is sufficient to allow substantial particle clearance from the lungs e.g. via the mucociliary pathway; in humans a delay of at least about 4 days is preferred.
- the image generation may be by conventional techniques, e.g. X-ray CT, B-mode ultrasound, spin-echo MRI, etc.
- gas-containing contrast agents e.g. with envelopes similar to that in Schering AG's Cavisome product
- increased ultrasound intensity may be used to burst particles contained in the lymph nodes and the ultrasound signal from the bursts may be imaged using the "popcorn" technique.
- the contrast agent may be delivered together with a therapeutic agent (e.g. a cytotoxic or gene therapy agent) where lung cancer has already been diagnosed.
- a therapeutic agent e.g. a cytotoxic or gene therapy agent
- the therapeutic agent e.g. cisplatin
- the therapeutic agent may be in dissolved or more preferably particulate form and if particulate it and the contrast may be in the same or different particles.
- a therapeutic agent may be encapsulated within a contrast agent which is in vesicle form, it may be coated onto or in the pores of a contrast agent in solid form, or it may be bound to the surface of a contrast agent particle .
- the dosage of therapeutic agent required will be dependent on the particular agent chosen and may for example be the same or less than the conventional dosage for the selected agent .
- the invention provides a method of imaging and treatment of lung cancer, said method comprising administering into the lungs of an affected animal a particulate composition comprising therapeutically and diagnostically effective amounts of a therapeutic agent and a physiologically tolerable, substantially water-insoluble, particulate contrast agent and after a period of time sufficient for uptake of particles of said contrast agent by lung draining lymph nodes generating an image of at least part of the lungs of said animal, e.g. by using an X- ray, MR, nuclear or ultrasound diagnostic imaging modality.
- the use of direct instillation to administer particulate therapeutic agents into the lung is also a further aspect of the invention.
- the invention provides a method of treatment of the human or non-human animal body comprising direct instillation of a particulate therapeutic agent into the lung of said animal e.g. to the region of a lesion of interest within the lung or to the deep lung.
- Such therapy will be advantageous since, unlike subcutaneous injection where most of the dose remains for a time at the injection site, direct instillation in the lung will be followed by rapid dispersion within the lung due to the presence of the lung surfactant itself and movement out of the lung via the bronchociliary pathway .
- CT-X-ray enables both morphology and filling defects in the lymph nodes to be imaged in vivo at or below millimetre dimensions.
- MRI will allow excellent contrast at particle dosage levels below those required for CT. This will also be true of radiopharmaceuticals (containing longer lived isotopes such as indium or iodine isotopes, rather than technecium) used in nuclear medicine imaging techniques, e.g. gamma imaging.
- Figure 1 is a schematic diagram of the lungs in the dog; and Figures 2 and 3 are X-ray CT images of the dog lung at 9 and 16 days post contrast administration.
- Example 1 Three beagle dogs were instilled with the suspension of Example 1.
- the instillations were carried out via bronchoscope as follows: 1.5ml in the lower left lobe, 3 x 1.5ml in the right lower lobe, 1.5ml vehicle only in the small, central lower lobe, and 1.5ml of saline in the upper left lobe. (See Figure 1).
- the instillations were video taped via the bronchoscope with no adverse events associated with the instillation.
- the anaesthetized dogs were imaged by conventional X-ray to view the placement of the test agent .
- the dogs were then returned to their cages . Thereafter, the dogs were imaged by Computed Tomography (CT) .
- CT Computed Tomography
- the dogs were again imaged by conventional X-ray and sacrificed on day 17 for morphologic and histopathologic evaluation of the lung tissues .
- Example 2 Three beagle dogs were instilled with the suspension of Example 2. The instillations were carried out via bronchoscope as follows: 1.5ml in the lower left lobe, 3 x 1.5ml in the lower right lobe, 1.5ml vehicle only in the small, central lower lobe, and 1.5ml of saline in the upper left lobe. (See Figure 1). The instillations were video taped via the bronchoscope with no adverse events associated with the instillation. Immediately after instillation, the anaesthetized dogs were imaged by conventional X-ray to view the placement of the test agent . The dogs were then returned to their cages . Thereafter, the dogs were imaged by Computed Tomography (CT) .
- CT Computed Tomography
- the dogs were again imaged by conventional X-ray and sacrificed on day 35 for morphologic and histopathologic evaluation of the lung tissues .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nanotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Radiology & Medical Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98922945A EP0975372A1 (en) | 1997-05-22 | 1998-05-22 | Contrast media for imaging of lung draining lymph nodes, administered through the lungs |
JP55013898A JP2001525846A (en) | 1997-05-22 | 1998-05-22 | Contrast agent |
AU75405/98A AU7540598A (en) | 1997-05-22 | 1998-05-22 | Contrast media |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9710604.1A GB9710604D0 (en) | 1997-05-22 | 1997-05-22 | Contrast media |
GB9710604.1 | 1997-05-22 | ||
US4917497P | 1997-06-09 | 1997-06-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998052617A2 true WO1998052617A2 (en) | 1998-11-26 |
WO1998052617A3 WO1998052617A3 (en) | 1999-08-12 |
Family
ID=10812900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/001489 WO1998052617A2 (en) | 1997-05-22 | 1998-05-22 | Contrast media for imaging of lung draining lymph nodes, administered through the lungs |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0975372A1 (en) |
JP (1) | JP2001525846A (en) |
AU (1) | AU7540598A (en) |
GB (1) | GB9710604D0 (en) |
WO (1) | WO1998052617A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003026702A1 (en) * | 2001-09-25 | 2003-04-03 | Upperton Limited | Particulate imaging contrast agents |
US8277391B2 (en) | 1994-09-16 | 2012-10-02 | Devicor Medical Products, Inc. | Methods and devices for defining and marking tissue |
US9492570B2 (en) | 1998-12-24 | 2016-11-15 | Devicor Medical Products, Inc. | Device and method for safe location and marking of a biopsy cavity |
US9669113B1 (en) | 1998-12-24 | 2017-06-06 | Devicor Medical Products, Inc. | Device and method for safe location and marking of a biopsy cavity |
US9986974B2 (en) | 1998-12-24 | 2018-06-05 | Devicor Medical Products, Inc. | Biopsy cavity marking device |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4911690A (en) * | 1985-03-29 | 1990-03-27 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatment or diagnosis by endoscopic administration into the lymphatics |
EP0387154A1 (en) * | 1989-03-08 | 1990-09-12 | Pierre Fabre Medicament | Aerosol compositions for the imaging, diagnosis and targetted therapy of inflamed and tumoral focuses |
EP0498482A2 (en) * | 1991-01-25 | 1992-08-12 | NanoSystems L.L.C. | X-ray contrast compositions useful in medical imaging |
EP0602691A2 (en) * | 1992-12-15 | 1994-06-22 | NanoSystems L.L.C. | Controlled precipitation of particulate diagnostic imaging contrast agents |
US5525328A (en) * | 1994-06-24 | 1996-06-11 | Nanosystems L.L.C. | Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging |
WO1996025918A1 (en) * | 1995-02-24 | 1996-08-29 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
WO1997013503A1 (en) * | 1995-10-13 | 1997-04-17 | The Penn State Research Foundation | Synthesis of drug nanoparticles by spray drying |
-
1997
- 1997-05-22 GB GBGB9710604.1A patent/GB9710604D0/en active Pending
-
1998
- 1998-05-22 EP EP98922945A patent/EP0975372A1/en not_active Withdrawn
- 1998-05-22 JP JP55013898A patent/JP2001525846A/en active Pending
- 1998-05-22 AU AU75405/98A patent/AU7540598A/en not_active Abandoned
- 1998-05-22 WO PCT/GB1998/001489 patent/WO1998052617A2/en not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4911690A (en) * | 1985-03-29 | 1990-03-27 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatment or diagnosis by endoscopic administration into the lymphatics |
EP0387154A1 (en) * | 1989-03-08 | 1990-09-12 | Pierre Fabre Medicament | Aerosol compositions for the imaging, diagnosis and targetted therapy of inflamed and tumoral focuses |
EP0498482A2 (en) * | 1991-01-25 | 1992-08-12 | NanoSystems L.L.C. | X-ray contrast compositions useful in medical imaging |
EP0602691A2 (en) * | 1992-12-15 | 1994-06-22 | NanoSystems L.L.C. | Controlled precipitation of particulate diagnostic imaging contrast agents |
US5525328A (en) * | 1994-06-24 | 1996-06-11 | Nanosystems L.L.C. | Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging |
WO1996025918A1 (en) * | 1995-02-24 | 1996-08-29 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
WO1997013503A1 (en) * | 1995-10-13 | 1997-04-17 | The Penn State Research Foundation | Synthesis of drug nanoparticles by spray drying |
Non-Patent Citations (5)
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8277391B2 (en) | 1994-09-16 | 2012-10-02 | Devicor Medical Products, Inc. | Methods and devices for defining and marking tissue |
US9492570B2 (en) | 1998-12-24 | 2016-11-15 | Devicor Medical Products, Inc. | Device and method for safe location and marking of a biopsy cavity |
US9669113B1 (en) | 1998-12-24 | 2017-06-06 | Devicor Medical Products, Inc. | Device and method for safe location and marking of a biopsy cavity |
US9986974B2 (en) | 1998-12-24 | 2018-06-05 | Devicor Medical Products, Inc. | Biopsy cavity marking device |
WO2003026702A1 (en) * | 2001-09-25 | 2003-04-03 | Upperton Limited | Particulate imaging contrast agents |
Also Published As
Publication number | Publication date |
---|---|
AU7540598A (en) | 1998-12-11 |
JP2001525846A (en) | 2001-12-11 |
GB9710604D0 (en) | 1997-07-16 |
WO1998052617A3 (en) | 1999-08-12 |
EP0975372A1 (en) | 2000-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lusic et al. | X-ray-computed tomography contrast agents | |
AU639466B2 (en) | Percutaneous lymphography | |
Krause | Delivery of diagnostic agents in computed tomography | |
Lee et al. | Nano‐sized CT contrast agents | |
CN1092989C (en) | Polymer-lipid microencapsulated gases for use as imaging agents | |
Cormode et al. | Nanoparticle contrast agents for computed tomography: a focus on micelles | |
Jakhmola et al. | Inorganic nanoparticles based contrast agents for X‐ray computed tomography | |
US20050265923A1 (en) | Embolus therapy using insoluble microparticles or vesicles containing contrast agents | |
WO2000033890A1 (en) | Particulate radiopaque contrast agent for microvascular x-ray imaging | |
Tilcock | Imaging tools: liposomal agents for nuclear medicine, computed tomography, magnetic resonance, and ultrasound | |
MISSELWITZ et al. | Magnetic resonance imaging of pulmonary ventilation: initial experiences with a gadolinium-DTPA-based aerosol | |
JP3759765B2 (en) | Liposome | |
US6001333A (en) | Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging | |
EP0881916A2 (en) | Contrast medium | |
Erdogan | Liposomal nanocarriers for tumor imaging | |
Owens et al. | CT and X-ray contrast agents: current clinical challenges and the future of contrast | |
EP0975372A1 (en) | Contrast media for imaging of lung draining lymph nodes, administered through the lungs | |
Caride et al. | Brominated radiopaque liposomes: contrast agent for computed tomography of liver and spleen a preliminary report | |
WHITE et al. | Biodistribution and clearance of contrast-carrying MREV liposomes | |
Gazelle et al. | Hepatic imaging with iodinated nanoparticles: a comparison with iohexol in rabbits | |
CA2212162A1 (en) | Liposomes that contain contrast media for the visualization of intravascular space | |
FISCHER | Particles | |
Wolf | Design of X-ray Contrast Agents | |
Cruje | Lanthanide Nanoparticles as Contrast Agents for In Vivo Dual Energy Microcomputed Tomography of the Mouse Vasculature | |
TORCHILIN | Liposomes as carriers of contrast agents for in vivo diagnostics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
ENP | Entry into the national phase in: |
Ref country code: JP Ref document number: 1998 550138 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09443345 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998922945 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998922945 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase in: |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998922945 Country of ref document: EP |